Atossa Therapeutics Regains Nasdaq Compliance, Averting Delisting
ATOS is trading near its 52-week low of $3.76 (10% above the low).
Summary
Atossa Therapeutics announced it has regained compliance with Nasdaq's minimum bid price rule, ensuring its continued listing on The Nasdaq Capital Market.
Key Events · Corporate Governance and Compliance · ATOS
-
Regained Nasdaq Compliance
The company received a letter from Nasdaq confirming it had regained compliance with Listing Rule 5550(a)(2) by maintaining a minimum closing bid price of $1.00 for at least 10 consecutive trading days, met as of February 13, 2026.
-
Averts Delisting Threat
This action resolves the previously disclosed non-compliance issue from February 21, 2025, and ensures the company's common stock will continue to be listed and traded on The Nasdaq Capital Market.
-
Follows Reverse Stock Split
This successful compliance follows the 15:1 reverse stock split announced on January 26, 2026, which was a key measure to increase the per-share price and meet Nasdaq's listing standards.
Analysis · ATOS · Life Sciences
Atossa Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement, a critical development that removes the immediate threat of delisting. This positive outcome follows the company's 15:1 reverse stock split, which became effective on February 2, 2026, and was a strategic move to address the non-compliance. Continued listing on Nasdaq provides stability and maintains the company's access to a major exchange, which is important for investor confidence and liquidity, especially for a life sciences company focused on product development.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATOS was trading at $4.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.7M. The 52-week trading range was $3.76 to $19.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.